Genocea to Host Quarterly Corporate Update Conference Call & Webcast on April 30th at 9:00 am ET
Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 4864999. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website at https://ir.genocea.com/events-and-presentations.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.
Genocea's mission is to help conquer cancer by designing and delivering targeted cancer vaccines and immunotherapies. The company has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on individual patient immune responses. Genocea’s lead neoantigen vaccine candidate, GEN-009, is currently being evaluated in a Phase 1/2a clinical trial. The company is also developing GEN-011, an investigational adoptive T cell therapy. To learn more, please visit www.genocea.com.
Source: Genocea Biosciences, Inc.